What is Lokelma primarily used for in the context of ESRD?

Lokelma is primarily used for treating hyperkalemia, which is an elevated level of potassium in the blood. In the context of End-Stage Renal Disease (ESRD), patients often experience impaired kidney function, leading to difficulties in excreting potassium. This accumulation can result in serious cardiac and muscular complications, making the management of potassium levels crucial in these patients.

Lokelma acts as a potassium-binding agent, which helps to lower serum potassium concentrations by binding to potassium in the gastrointestinal tract and facilitating its elimination from the body through feces. This mechanism is particularly beneficial in patients with ESRD, as their kidneys are less capable of processing and excreting excess potassium effectively. Thus, the primary role of Lokelma in this context is to help manage hyperkalemia, ensuring that patients maintain safer potassium levels and reducing the risk of associated complications.

Understanding the specific role of Lokelma highlights its significance in the overall management of cardiovascular health and metabolic balance in patients suffering from ESRD. Other options may refer to different treatments or conditions that are not directly related to its primary use in treating hyperkalemia.